Trial Profile
A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms JAVELIN Solid Tumor Japan
- Sponsors Merck KGaA; Merck Serono
- 17 Dec 2021 Results from pooled data from JAVELIN 62 Merkel 200, JAVELIN Solid Tumor, and JAVELIN Solid Tumor JPN assessing (PK)-tumor growth dynamics (TGD) analysis published in the Clinical Cancer Research
- 21 Oct 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2019 Results assessing pharmacokinetic/ pharmacodynamic analyses for avelumab comparing weight-based dosing from 3 clinical trials (NCT01772004, NCT01943461, and NCT02155647) published in the Clinical Pharmacology and Therapeutics